Mycophenolsäure Accord (Mycophenolic Acid)

Mycophenolic Acid, the active ingredient in Mycophenolsäure Accord, is an antimetabolite immunosuppressant presented as an oral formulation for systemic use. It is employed to prevent organ transplant rejection and to treat certain autoimmune diseases such as lupus nephritis in adult patients. GNH USA supplies Mycophenolsäure Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolic Acid acts on the immune system to reduce lymphocyte proliferation, making it useful in transplant and autoimmune settings. - Organ transplant rejection: helps prevent graft rejection by suppressing immune activation. - Lupus nephritis: reduces renal inflammation and proteinuria in patients with systemic lupus erythematosus. - Other autoimmune diseases: may be employed off‑label for conditions such as vasculitis where immune suppression is required.

Mycophenolic Acid can cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools, sometimes leading to dehydration. - Headache: transient tension‑type headaches. - Anemia: reduced red blood cell count causing fatigue.

Serious or Rare Side Effects: - Severe infections: opportunistic infections due to immunosuppression. - Bone marrow suppression: pancytopenia with risk of bleeding. - Hepatotoxicity: elevated liver enzymes or liver injury. - Progressive multifocal leukoencephalopathy (PML): rare but life‑threatening brain infection.

Patients receiving Mycophenolsäure Accord should be monitored closely for safety concerns. - Blood counts: regular CBC to detect leukopenia or anemia. - Renal function: assess serum creatinine and eGFR periodically. - Liver enzymes: monitor ALT/AST for signs of hepatotoxicity. - Live vaccines: avoid administration while on therapy. - Dose adjustments: consider in hepatic impairment or severe renal dysfunction. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Mycophenolic Acid interacts with several medicines that can alter its efficacy or safety.

Major Interactions (Avoid): - Azathioprine: additive bone marrow suppression. - Cyclosporine or tacrolimus: increased risk of nephrotoxicity and infection.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Antacids containing aluminum or magnesium: can reduce absorption, separate dosing by at least 2 hours. - Rifampin: induces metabolism, potentially lowering drug levels.